Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20855072rdf:typepubmed:Citationlld:pubmed
pubmed-article:20855072lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C0020557lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C0027996lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C0205251lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C2698651lld:lifeskim
pubmed-article:20855072lifeskim:mentionsumls-concept:C1254298lld:lifeskim
pubmed-article:20855072pubmed:issue1lld:pubmed
pubmed-article:20855072pubmed:dateCreated2010-10-25lld:pubmed
pubmed-article:20855072pubmed:abstractTextAtherogenic dyslipidemia is emerging as a target of lipid-modifying therapy. However, an optimal pharmacologic approach has not yet been established. The aim of this study is to compare the efficacy and tolerability of the typical doses of fenofibrate and niacin.lld:pubmed
pubmed-article:20855072pubmed:languageenglld:pubmed
pubmed-article:20855072pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:citationSubsetIMlld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20855072pubmed:statusMEDLINElld:pubmed
pubmed-article:20855072pubmed:monthNovlld:pubmed
pubmed-article:20855072pubmed:issn1879-1484lld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:LiL TLTlld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:JangYangsooYlld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:ChungNamsikNlld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:KangSeok-MinS...lld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:ChoSeung-YunS...lld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:ShimWon-HeumW...lld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:LeeSang-HakSHlld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:ParkSunghaSlld:pubmed
pubmed-article:20855072pubmed:authorpubmed-author:KimJong-YounJ...lld:pubmed
pubmed-article:20855072pubmed:copyrightInfoCopyright © 2010 Elsevier Ireland Ltd. All rights reserved.lld:pubmed
pubmed-article:20855072pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20855072pubmed:volume213lld:pubmed
pubmed-article:20855072pubmed:ownerNLMlld:pubmed
pubmed-article:20855072pubmed:authorsCompleteYlld:pubmed
pubmed-article:20855072pubmed:pagination235-40lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:meshHeadingpubmed-meshheading:20855072...lld:pubmed
pubmed-article:20855072pubmed:year2010lld:pubmed
pubmed-article:20855072pubmed:articleTitleOptimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.lld:pubmed
pubmed-article:20855072pubmed:affiliationCardiology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.lld:pubmed
pubmed-article:20855072pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20855072pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:20855072pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed